Clinical trials: HPV
HIV Infections
A Clinical Trial to Evaluate the Immunogenicity of the Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017
Phase IV, open, multicenter and single-arm clinical trial designed to evaluate the immunogenicity of the HPV9v vaccine in men with HIV infection (HIV +) who have sex with men (MSM)
- Trial name
- GESIDA10017 (NCT03626467)
- Testing
- HPV9v
- Where
- 3 sites in Spain
- Volunteers
- 158 people
- Sponsor
- Fundacion SEIMC-GESIDA
HIV Infections, Anal Cancer
Screening for HIV-Associated Anal Cancer
Cancer of the anus occurs at very high rates in young men with HIV and is caused by a virus called human papillomavirus (HPV). Anal cancer has increased during the HIV epidemic despite effective therapies for HIV.
- Conditions
- HIV Infections, Anal Cancer, Anal Dysplasia, Papillomavirus Infections
- Trial name
- TRACE (NCT00188292)
- Where
- Canada
- Volunteers
- 401 people
- Sponsor
- University Health Network, Toronto
HPV Infection, HPV Vaccine
Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity
This is a multi-center, open, prospective cohort study that aims to investigate the immunogenicity and immune persistence of two different domestically produced bivalent HPV vaccines compared with an imported HPV vaccine in women…
- Conditions
- HPV Infection, HPV Vaccine, Cervical Cancer Prevention
- Trial name
- NCT06137352
- Testing
- Follow up
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fujian Maternity and Child Health Hospital
HPV Infections
Significance of the High-risk Hpv Viral Load
The aim of this study is to evaluate the significance of an elevated high-risk HPV (HR-HPV) viral load.
- Trial name
- NCT00682812
- Testing
- 2 cervical takings and 2 sampling of blood
- Where
- France
- Volunteers
- 149 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Cervical Cancer
Distribution of Human Papillomavirus (HPV) Genotypes in Patients With Cervical Cancer From Croatia
Human papillomavirus (HPV) of high-risk genotype is a necessary risk factor in development of cervical cancer. There is a vaccine available to prevent cervical lesions associated with high-risk HPV genotypes 16 and 18.
- Trial name
- HPV-cancer (NCT01385436)
- Where
- Croatia
- Volunteers
- 400 people
- Sponsor
- University Hospital for Infectious Diseases, Croatia
Cervical Cancer Screening, Human Papilloma Virus
Developing and Implementing HPV SCREENED
This study will assess the feasibility of implementing HPV self-sampling as a primary cervical cancer screening strategy for under-screened women in the emergency department (ED).
- Trial name
- NCT07657104
- Testing
- HPV Self-collection in the ED
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Cervical Cancer Prevention, Cervical Cancer
A Cervical Cancer Prevention Program in Kenya
Cervical cancer is caused by oncogenic, or "high-risk" (HR) human papillomavirus (HPV), and is the main cause of cancer-related death among Kenyan women.
- Trial name
- Merck-3 (NCT06411938)
- Testing
- High Risk HPV DNA Testing, Visual Inspection with acetic acid (VIA) and possible cervical biopsy, Gardisil-9
- Where
- Kenya
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- Indiana University
HPV Infections
A Phase I Study of Quadrivalent HPV Recombinant Vaccine
To evaluate the safety and primary immunogenicity of the quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (hansenula polymorpha) in Chinese female subjects aged 9-45 years.
- Trial name
- NCT03085381
- Testing
- HPV vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Papilloma Viral Infection, CIN1
Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)
HPV infection can lead to cancer, especially when precancerous lesions have developed and high-risk HPV is present. Glizigen is an oral and intravaginal treatment based on activated glycyrrhizinic acid that has shown potential…
- Conditions
- Papilloma Viral Infection, CIN1, LSIL, Low Grade Squamous Intraepithelial Lesion
- Trial name
- NCT05916911
- Testing
- Glizigen
- Where
- 4 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Catalysis SL
Cervical Intraepithelial Neoplasia, Cervix Uteri Cancer
Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities
The goal of this observational study is to assess the five-year incidence of histologically confirmed cervical cancer among women who test positive for human papillomavirus (HPV) with low-grade cytological abnormalities, to…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervix Uteri Cancer, Human Papilloma Virus, Cervix Carcinoma
- Trial name
- NCT07259616
- Volunteers
- 46,079 people
- Sponsor
- Gynaecologisch Oncologisch Centrum Zuid
HPV
Human Papillomavirus (HPV) Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers
This will enroll 300 mothers of teenage girls and boys to identify barriers to HPV vaccination among low-income, African-American teens.
- Trial name
- NCT00680147
- Testing
- brief informational intervention to promote HPV vaccine acceptance
- Where
- United States
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- Syracuse University
Human Papillomavirus
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
Background: Most symptoms of human papillomaviruses (HPV) infection, do not cause serious health problems, but some do. As HPV can cause uncontrolled growth of infected cells, some people can develop benign skin lesions, larger…
- Trial name
- NCT05026138
- Where
- United States
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cervical Intraepithelial Neoplasia
Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia
The purpose of this study is to determine the optimal dose of GX-188E for the Phase 3 and access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 3 (CIN3).
- Trial name
- NCT02139267
- Testing
- GX-188E
- Where
- 4 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Genexine, Inc.
Papillomavirus Infections
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
- Trial name
- NCT00117884
- Testing
- 851B
- Where
- 23 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Takeda
HPV Infection, Cervical Disease
Impact of HPV Vaccination on HPV Infection and Cervical Related Disease Burden in Real-World Settings (HPV-RWS)
Take AS04 adjuvanted HPV16/18 vaccine as an example to evaluate the impact of HPV vaccination on HPV infection and related disease burden in the real world based on prospective cohort and Yinzhou Regional Health Information…
- Trial name
- HPV-RWS (NCT05341284)
- Testing
- Questionnaire Survey and Cervical Cancer Screening
- Volunteers
- healthy volunteers welcome
- Sponsor
- Peking University
Parents, Parent-Child Relations
Development and Psychometric Testing of HPV Knowledge Scale
The aim of this study is to develop and conduct psychometric testing of a new scale, the Human Papillomavirus Knowledge Scale (HPV-KS), particularly designed to assess HPV knowledge among parents of school-age children in…
- Trial name
- NCT06466252
- Testing
- Psychometric Group
- Where
- Indonesia
- Volunteers
- 673 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University
Warts
Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts
The investigators explore the role of the complement pathway and T helper 1 immune response in clinical response to Candida immunotherapy via complement component and tumor necrosis factor, respectively.
- Trial name
- NCT04399577
- Testing
- Candida antigen
- Where
- Egypt
- Volunteers
- 39 people
- Sponsor
- Zagazig University
Verruca Viral
A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
Common warts are papulonodular epidermal lesions caused by human papillomavirus (HPV) usually by the strains 1, 2, 4, 27 or 57. Cutaneous warts occur in 7% to 10% of the general population, with a maximum incidence between 12 and…
- Trial name
- MMR (NCT04428359)
- Testing
- Measles-Mumps-Rubella Vaccine, Vit D
- Where
- Nepal
- Volunteers
- 66 people
- Sponsor
- B.P. Koirala Institute of Health Sciences
HPV Genital Infection (Primary Condition Studied), Bacterial Vaginosis
Kinetics and Ecology of Human Papillomavirus Genital Infections in Young Women
Most genital infections by human papillomaviruses (HPV) are asymptomatic or benign and clear within a few months or years. There infections are much less studies than chronic infections, even though they represent the main…
- Conditions
- HPV Genital Infection (Primary Condition Studied), Bacterial Vaginosis, Chlamydiae Infection
- Trial name
- PAPCLEAR (NCT02946346)
- Testing
- vaginal sampling
- Where
- France
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Human Papillomavirus Infection, HPV Vaccines
The Role of Cyberchondria Severity in the Relationship Between HPV Awareness and Vaccination Attitudes in Adult Women
Human papillomavirus (HPV) is a prevalent sexually transmitted infection linked to nearly all cases (99%) of cervical cancer. Prophylactic HPV vaccination is effective in preventing these cancers, complemented by HPV screening…
- Conditions
- Human Papillomavirus Infection, HPV Vaccines, Cyberchondria, Awareness
- Trial name
- NCT06800456
- Where
- Turkey (Türkiye)
- Volunteers
- 337 people
- Sponsor
- Acibadem University